HSP90 Cancer Research Results

HSP90, HSP90: Click to Expand ⟱
Source: HalifaxProj(inhibit)
Type:
Heat shock protein 90 (Hsp90) is a molecular chaperone that plays a critical role in the proper folding, stabilization, and function of many proteins, including those involved in cell signaling, cell cycle regulation, and stress responses.
-Hsp90 interacts with a variety of client proteins that are often mutated or overexpressed in cancer. These include oncogenes (like HER2, BRAF, and AKT) and tumor suppressor proteins (like p53).
-Hsp90 is often overexpressed in cancer cells, which can help them survive under stressful conditions, such as those found in the tumor microenvironment. This overexpression is associated with poor prognosis in several types of cancer.
-HSPs, particularly HSP90, are known to stabilize many proteins that drive cancer progression (oncoproteins).
Var, Various Cancer: Click to Expand ⟱
Cyclooxygenase (COX)-2 overexpression has been noted in various cancers. PI3Ks/AKT pathways are over-activated in several types of cancers.
EGFR altered activity has been noted in various pathological conditions. However, its regulation is an important step in the inhibition of cancer. In this regard, EGCG shows a pivotal role in the inhibition of EGFR activity.
Activating protein-1 transcription factor has been associated with pathogenesis including cancer.
Activation of the sonic hedgehog (Shh) pathway is required for the growth of numerous tissues and organs and recent evidence indicates that this pathway is often recruited to stimulate growth of cancer stem cells (CSCs) and to orchestrate the reprogramming of cancer cells via epithelial mesenchymal transition (EMT). Increased expression of Nanog has been associated with the aggressive nature of certain cancers, highlighting its role in promoting cancer stem cell characteristics.
The aberrant hedgehog (Hh)/GLI signaling pathway causes the formation and progression of a variety of tumors.
The process of cell apoptosis is often accompanied by the destruction of mitochondrial transmembrane potential, which is widely regarded as one of the earliest events in the process of cell apoptosis.
Human malignancies frequently exhibit mutations in the TGF-β pathway, and overactivation of this system is linked to tumor growth by promoting angiogenesis and inhibiting the innate and adaptive antitumor immune responses50.
Several studies have demonstrated that high cyclin D1 expression was observed in cancers including breast, lung, prostate, lymph node and colorectal cancers [23–25].
The oncogene c-myc, which is frequently over-expressed in cancer cells, is involved in the transactivation of most of the glycolytic enzymes including lactate dehydrogenase A (LDHA) and the glucose transporter GLUT1 [51,52]. Thus, c-myc activation is a likely candidate to promote the enhanced glucose uptake and lactate release in the proliferating cancer cell.
Vimentin is overexpressed in various epithelial cancers, including prostate cancer, gastrointestinal tumors, tumors of the central nervous system, breast cancer, malignant melanoma, and lung cancer. Vimentin’s overexpression in cancer correlates well with accelerated tumor growth, invasion, and poor prognosis; however, the role of vimentin in cancer progression remains obscure.
Heat shock proteins (HSPs) are normally induced under environmental stress to serve as chaperones for maintenance of correct protein folding but they are often overexpressed in many cancers, including breast cancer.
Since NQO1 is highly expressed in many solid tumors, including via upregulation of Nrf2, the design of compounds activated by NQO1 and NQO1-targeted drug delivery have been active areas of research.
Since increased Nrf2 gene expression is one of the main mechanisms of cancer cells in resisting chemotherapeutic drugs and survival in oxidative conditions; finding compounds with the ability to suppress Nrf2 gene expression with minimum side effects can be considered an important strategy for increasing the sensitivity of cancer cells to chemotherapy.
Overexpression of c-met stimulates proliferation, migration and invasion in various types of cancer including prostate cancer.
Overexpression of TGFα and EGFR by many carcinomas correlates with the development of cancer metastasis, resistance to chemotherapy and poor prognosis.
More than 50% of human cancers have a mutated nonfunctional p53.


Scientific Papers found: Click to Expand⟱
3155- Ash,    Overview of the anticancer activity of withaferin A, an active constituent of the Indian ginseng Withania somnifera
- Review, Var, NA
Half-Life↝, Inflam↓, antiOx↓, angioG↓, ROS↑, BAX↑, Bak↑, E6↓, E7↓, P53↑, Casp3↑, cl‑PARP↑, STAT3↓, eff↑, HSP90↓, TGF-β↓, TNF-α↓, EMT↑, mTOR↓, NOTCH1↓, p‑Akt↓, NF-kB↓, Dose↝,
3156- Ash,    Withaferin A: From ayurvedic folk medicine to preclinical anti-cancer drug
- Review, Var, NA
MAPK↑, p38↑, BAX↑, BIM↑, CHOP↑, ROS↑, DR5↑, Apoptosis↑, Ferroptosis↑, GPx4↓, BioAv↝, HSP90↓, RET↓, E6↓, E7↓, Akt↓, cMET↓, Glycolysis↓, TCA↓, NOTCH1↓, STAT3↓, AP-1↓, PI3K↓, eIF2α↓, HO-1↑, TumCCA↑, CDK1↓, *hepatoP↑, *GSH↑, *NRF2↑, Wnt↓, EMT↓, uPA↓, CSCs↓, Nanog↓, SOX2↓, CD44↓, lactateProd↓, Iron↑, NF-kB↓,
3160- Ash,    Withaferin A: A Pleiotropic Anticancer Agent from the Indian Medicinal Plant Withania somnifera (L.) Dunal
- Review, Var, NA
TumCCA↑, H3↑, P21↑, cycA1/CCNA1↓, CycB/CCNB1↓, cycE/CCNE↓, CDC2↓, CHK1↓, Chk2↓, p38↑, MAPK↑, E6↓, E7↓, P53↑, Akt↓, FOXO3↑, ROS↑, γH2AX↑, MMP↓, mitResp↓, eff↑, TumCD↑, Mcl-1↓, ER Stress↑, ATF4↑, ATF3↑, CHOP↑, NOTCH↓, NF-kB↓, Bcl-2↓, STAT3↓, CDK1↓, β-catenin/ZEB1↓, N-cadherin↓, EMT↓, Cyt‑c↑, eff↑, CDK4↓, p‑RB1↓, PARP↑, cl‑Casp3↑, cl‑Casp9↑, NRF2↑, ER-α36↓, LDHA↓, lipid-P↑, AP-1↓, COX2↓, RenoP↑, PDGFR-BB↓, SIRT3↑, MMP2↓, MMP9↓, NADPH↑, NQO1↑, GSR↑, HO-1↑, *SOD2↑, *Prx↑, *Casp3?, eff↑, Snail↓, Slug↓, Vim↓, CSCs↓, HEY1↓, MMPs↓, VEGF↓, uPA↓, *toxicity↓, CDK2↓, CDK4↓, HSP90↓,
3166- Ash,    Exploring the Multifaceted Therapeutic Potential of Withaferin A and Its Derivatives
- Review, Var, NA
*p‑PPARγ↓, *cardioP↑, *AMPK↑, *BioAv↝, *Half-Life↝, *Half-Life↝, *Dose↑, *chemoPv↑, IL6↓, STAT3↓, ROS↓, OXPHOS↓, PCNA↓, LDH↓, AMPK↑, TumCCA↑, NOTCH3↓, Akt↓, Bcl-2↓, Casp3↑, Apoptosis↑, eff↑, NF-kB↓, CSCs↓, HSP90↓, PI3K↓, FOXO3↑, β-catenin/ZEB1↓, N-cadherin↓, EMT↓, FASN↓, ACLY↓, ROS↑, NRF2↑, HO-1↑, NQO1↑, JNK↑, mTOR↓, neuroP↑, *TNF-α↓, *IL1β↓, *IL6↓, *IL8↓, *IL18↓, RadioS↑, eff↑,
3162- Ash,    Molecular insights into cancer therapeutic effects of the dietary medicinal phytochemical withaferin A
- Review, Var, NA
lipid-P↓, SOD↑, GPx↑, P53↑, Bcl-2↑, E6↓, E7↓, pRB↑, CycB/CCNB1↑, CDC2↑, P21↑, PCNA↓, ALDH1A1↓, Vim↓, Glycolysis↓, cMyc↓, BAX↑, NF-kB↓, Casp3↑, CHOP↑, DR5↑, ERK↓, Wnt↓, β-catenin/ZEB1↓, Akt↓, HSP90↓,
1358- Ash,    Withaferin A: A Dietary Supplement with Promising Potential as an Anti-Tumor Therapeutic for Cancer Treatment - Pharmacology and Mechanisms
- Review, Var, NA
TumCCA↑, Apoptosis↑, TumAuto↑, Ferroptosis↑, TumCP↓, CSCs↓, TumMeta↓, EMT↓, angioG↓, Vim↓, HSP90↓, annexin II↓, m-FAM72A↓, BCR-ABL↓, Mortalin↓, NRF2↓, cMYB↓, ROS↑, ChemoSen↑, eff↑, ChemoSen↑, ChemoSen↑, eff↑, *BioAv↓, ROCK1↓, TumCI↓, Sp1/3/4↓, VEGF↓, Hif1a↓, EGFR↓,
5938- Cela,    Celastrol: A Review of Useful Strategies Overcoming its Limitation in Anticancer Application
- Review, Var, NA
AntiCan↑, BioAv↓, Apoptosis↑, TumAuto↑, TumCCA↑, TumMeta↓, angioG↓, Inflam↓, antiOx↑, ChemoSen↑, HSP90↓, ROS↑, RadioS↑, P53↑, NLRP3↓,
5945- Cela,    Targeting the dynamic HSP90 complex in cancer
- Review, Var, NA
HSP90↓,
5950- Cela,    Anticancer Inhibitors of Hsp90 Function: Beyond the Usual Suspects
- Review, Var, NA
ChemoSen↑, HSP90↓, Akt↓, CDK4↓,
2653- Cela,    Oxidative Stress Inducers in Cancer Therapy: Preclinical and Clinical Evidence
- Review, Var, NA
chemoPv↑, Catalase↑, ROS↑, HSP90↓, Sp1/3/4↓, AMPK↑, P53↑, JNK↑, ER Stress↑, MMP↓, TumCCA↑, TumAuto↑, Hif1a↑, Akt↑, other↓, Prx↓,
1442- Deg,    Deguelin, a novel anti-tumorigenic agent targeting apoptosis, cell cycle arrest and anti-angiogenesis for cancer chemoprevention
- Review, Var, NA
PI3K/Akt↓, IKKα↓, AMP↓, mTOR↓, survivin↓, NF-kB↓, Apoptosis↑, TumCCA↑, toxicity↓, HSP90↓, Casp↑, TumCG↓, p27↑, cycE/CCNE↓, angioG↓, Hif1a↓, VEGF↓, *toxicity↑,
5152- GamB,    Gambogic Acid as a Candidate for Cancer Therapy: A Review
- Review, Var, NA
AntiCan↑, Apoptosis↑, TumAuto↑, TumCCA↑, TumCI↓, TumMeta↓, angioG↓, eff↑, NF-kB↓, P53↑, P21↑, MDM2↓, HSP90↓, Bcl-2↓, Cyt‑c↑, Casp↑, MMP↓, Casp3↑, Casp9↑, cl‑PARP↑, Bax:Bcl2↑, ROS↑, SIRT1↓, TrxR1↓, Fas↓, FasL↑, FADD↑, APAF1↑, DNAdam↑, NF-kB↓, STAT3↓, MAPK↓, cFos↓, EGFR↓, Akt↓, mTOR↓, AMPK↑, TumCCA↑, ChemoSen↑, P-gp↓, survivin↓,
5148- GamB,    Gambogic acid: A shining natural compound to nanomedicine for cancer therapeutics
- Review, Var, NA
AntiCan↑, angioG↓, ChemoSen↑, RadioS↑, VEGF↓, MMP2↓, MMP9↓, Telomerase↓, TrxR↓, ERK↓, HSP90↓, ROS↑, SIRT1↑, survivin↓, cFLIP↓, Casp3↑, Casp8↑, Casp9↑, BAD↓, BID↓, Bcl-2↓, BAX↑, STAT3↓, hTERT/TERT↓, NF-kB↓, Myc↓, Hif1a↓, FOXD3↑, BioAv↓, BioAv↑, P53↑, eff↓, OCR↓, MMP↓, PI3K↓, Akt↓, BBB↑, TumCG↓, TumMeta↓, BioAv↑,
3343- QC,    Quercetin, a Flavonoid with Great Pharmacological Capacity
- Review, Var, NA - Review, AD, NA - Review, Arthritis, NA
*antiOx↑, *ROS↓, *angioG↓, *Inflam↓, *BioAv↓, *Half-Life↑, *GSH↑, *SOD↑, *Catalase↑, *Nrf1↑, *BP↓, *cardioP↑, *IL10↓, *TNF-α↓, *Aβ↓, *GSK‐3β↓, *tau↓, *neuroP↑, *Pain↓, *COX2↓, *NRF2↑, *HO-1↑, *IL1β↓, *IL17↓, *MCP1↓, PKCδ↓, ERK↓, BAX↓, cMyc↓, KRAS↓, ROS↓, selectivity↑, tumCV↓, Apoptosis↑, TumCCA↑, eff↑, P-gp↓, eff↑, eff↑, eff↑, eff↑, CycB/CCNB1↓, CDK1↓, CDK4↓, CDK2↓, TOP2↓, Cyt‑c↑, cl‑PARP↑, MMP↓, HSP70/HSPA5↓, HSP90↓, MDM2↓, RAS↓, eff↑,
1726- SFN,    Sulforaphane: A Broccoli Bioactive Phytocompound with Cancer Preventive Potential
- Review, Var, NA
Dose↝, eff↝, IL1β↓, IL6↓, IL12↓, TNF-α↓, COX2↓, CXCR4↓, MPO↓, HSP70/HSPA5↓, HSP90↓, VCAM-1↓, IKKα↓, NF-kB↓, HO-1↑, Casp3↑, Casp7↑, Casp8↑, Casp9↑, cl‑PARP↑, Cyt‑c↑, Diablo↑, CHOP↑, survivin↓, XIAP↓, p38↑, Fas↑, PUMA↑, VEGF↓, Hif1a↓, Twist↓, Zeb1↓, Vim↓, MMP2↓, MMP9↓, E-cadherin↑, N-cadherin↓, Snail↓, CD44↓, cycD1/CCND1↓, cycA1/CCNA1↓, CycB/CCNB1↓, cycE/CCNE↓, CDK4↓, CDK6↓, p50↓, P53↑, P21↑, GSH↑, SOD↑, GSTs↑, mTOR↓, Akt↓, PI3K↓, β-catenin/ZEB1↓, IGF-1↓, cMyc↓, CSCs↓,

Showing Research Papers: 1 to 15 of 15

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 15

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

antiOx↓, 1,   antiOx↑, 1,   ATF3↑, 1,   Catalase↑, 1,   Ferroptosis↑, 2,   GPx↑, 1,   GPx4↓, 1,   GSH↑, 1,   GSR↑, 1,   GSTs↑, 1,   HO-1↑, 4,   Iron↑, 1,   lipid-P↓, 1,   lipid-P↑, 1,   MPO↓, 1,   NQO1↑, 2,   NRF2↓, 1,   NRF2↑, 2,   OXPHOS↓, 1,   Prx↓, 1,   ROS↓, 2,   ROS↑, 9,   SIRT3↑, 1,   SOD↑, 2,   TrxR↓, 1,   TrxR1↓, 1,  

Mitochondria & Bioenergetics ⓘ

BCR-ABL↓, 1,   CDC2↓, 1,   CDC2↑, 1,   mitResp↓, 1,   MMP↓, 5,   Mortalin↓, 1,   OCR↓, 1,   XIAP↓, 1,  

Core Metabolism/Glycolysis ⓘ

ACLY↓, 1,   AMP↓, 1,   AMPK↑, 3,   cMyc↓, 3,   FASN↓, 1,   Glycolysis↓, 2,   lactateProd↓, 1,   LDH↓, 1,   LDHA↓, 1,   NADPH↑, 1,   PI3K/Akt↓, 1,   SIRT1↓, 1,   SIRT1↑, 1,   TCA↓, 1,  

Cell Death ⓘ

Akt↓, 8,   Akt↑, 1,   p‑Akt↓, 1,   APAF1↑, 1,   Apoptosis↑, 7,   BAD↓, 1,   Bak↑, 1,   BAX↓, 1,   BAX↑, 4,   Bax:Bcl2↑, 1,   Bcl-2↓, 4,   Bcl-2↑, 1,   BID↓, 1,   BIM↑, 1,   Casp↑, 2,   Casp3↑, 6,   cl‑Casp3↑, 1,   Casp7↑, 1,   Casp8↑, 2,   Casp9↑, 3,   cl‑Casp9↑, 1,   cFLIP↓, 1,   Chk2↓, 1,   Cyt‑c↑, 4,   Diablo↑, 1,   DR5↑, 2,   FADD↑, 1,   Fas↓, 1,   Fas↑, 1,   FasL↑, 1,   Ferroptosis↑, 2,   HEY1↓, 1,   hTERT/TERT↓, 1,   JNK↑, 2,   MAPK↓, 1,   MAPK↑, 2,   Mcl-1↓, 1,   MDM2↓, 2,   Myc↓, 1,   p27↑, 1,   p38↑, 3,   PUMA↑, 1,   survivin↓, 4,   Telomerase↓, 1,   TumCD↑, 1,  

Kinase & Signal Transduction ⓘ

FOXD3↑, 1,   RET↓, 1,   Sp1/3/4↓, 2,  

Transcription & Epigenetics ⓘ

H3↑, 1,   other↓, 1,   pRB↑, 1,   tumCV↓, 1,  

Protein Folding & ER Stress ⓘ

CHOP↑, 4,   eIF2α↓, 1,   ER Stress↑, 2,   HSP70/HSPA5↓, 2,   HSP90↓, 15,  

Autophagy & Lysosomes ⓘ

TumAuto↑, 4,  

DNA Damage & Repair ⓘ

CHK1↓, 1,   DNAdam↑, 1,   m-FAM72A↓, 1,   P53↑, 8,   PARP↑, 1,   cl‑PARP↑, 4,   PCNA↓, 2,   γH2AX↑, 1,  

Cell Cycle & Senescence ⓘ

CDK1↓, 3,   CDK2↓, 2,   CDK4↓, 5,   cycA1/CCNA1↓, 2,   CycB/CCNB1↓, 3,   CycB/CCNB1↑, 1,   cycD1/CCND1↓, 1,   cycE/CCNE↓, 3,   P21↑, 4,   p‑RB1↓, 1,   TumCCA↑, 10,  

Proliferation, Differentiation & Cell State ⓘ

ALDH1A1↓, 1,   CD44↓, 2,   cFos↓, 1,   cMET↓, 1,   cMYB↓, 1,   CSCs↓, 5,   EMT↓, 4,   EMT↑, 1,   ERK↓, 3,   FOXO3↑, 2,   IGF-1↓, 1,   mTOR↓, 5,   Nanog↓, 1,   NOTCH↓, 1,   NOTCH1↓, 2,   NOTCH3↓, 1,   PI3K↓, 4,   RAS↓, 1,   SOX2↓, 1,   STAT3↓, 6,   TOP2↓, 1,   TumCG↓, 2,   Wnt↓, 2,  

Migration ⓘ

annexin II↓, 1,   AP-1↓, 2,   E-cadherin↑, 1,   ER-α36↓, 1,   KRAS↓, 1,   MMP2↓, 3,   MMP9↓, 3,   MMPs↓, 1,   N-cadherin↓, 3,   PKCδ↓, 1,   ROCK1↓, 1,   Slug↓, 1,   Snail↓, 2,   TGF-β↓, 1,   TumCI↓, 2,   TumCP↓, 1,   TumMeta↓, 4,   Twist↓, 1,   uPA↓, 2,   VCAM-1↓, 1,   Vim↓, 4,   Zeb1↓, 1,   β-catenin/ZEB1↓, 4,  

Angiogenesis & Vasculature ⓘ

angioG↓, 6,   ATF4↑, 1,   EGFR↓, 2,   Hif1a↓, 4,   Hif1a↑, 1,   PDGFR-BB↓, 1,   VEGF↓, 5,  

Barriers & Transport ⓘ

BBB↑, 1,   P-gp↓, 2,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 2,   CXCR4↓, 1,   IKKα↓, 2,   IL12↓, 1,   IL1β↓, 1,   IL6↓, 2,   Inflam↓, 2,   NF-kB↓, 10,   p50↓, 1,   TNF-α↓, 2,  

Protein Aggregation ⓘ

NLRP3↓, 1,  

Hormonal & Nuclear Receptors ⓘ

CDK6↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 2,   BioAv↑, 2,   BioAv↝, 1,   ChemoSen↑, 7,   Dose↝, 2,   eff↓, 1,   eff↑, 15,   eff↝, 1,   Half-Life↝, 1,   RadioS↑, 3,   selectivity↑, 1,  

Clinical Biomarkers ⓘ

E6↓, 4,   E7↓, 4,   EGFR↓, 2,   hTERT/TERT↓, 1,   IL6↓, 2,   KRAS↓, 1,   LDH↓, 1,   Myc↓, 1,  

Functional Outcomes ⓘ

AntiCan↑, 3,   chemoPv↑, 1,   neuroP↑, 1,   RenoP↑, 1,   toxicity↓, 1,  
Total Targets: 216

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

antiOx↑, 1,   Catalase↑, 1,   GSH↑, 2,   HO-1↑, 1,   Nrf1↑, 1,   NRF2↑, 2,   Prx↑, 1,   ROS↓, 1,   SOD↑, 1,   SOD2↑, 1,  

Core Metabolism/Glycolysis ⓘ

AMPK↑, 1,   p‑PPARγ↓, 1,  

Cell Death ⓘ

Casp3?, 1,  

Proliferation, Differentiation & Cell State ⓘ

GSK‐3β↓, 1,  

Angiogenesis & Vasculature ⓘ

angioG↓, 1,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 1,   IL10↓, 1,   IL17↓, 1,   IL18↓, 1,   IL1β↓, 2,   IL6↓, 1,   IL8↓, 1,   Inflam↓, 1,   MCP1↓, 1,   TNF-α↓, 2,  

Synaptic & Neurotransmission ⓘ

tau↓, 1,  

Protein Aggregation ⓘ

Aβ↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 2,   BioAv↝, 1,   Dose↑, 1,   Half-Life↑, 1,   Half-Life↝, 2,  

Clinical Biomarkers ⓘ

BP↓, 1,   IL6↓, 1,  

Functional Outcomes ⓘ

cardioP↑, 2,   chemoPv↑, 1,   hepatoP↑, 1,   neuroP↑, 1,   Pain↓, 1,   toxicity↓, 1,   toxicity↑, 1,  
Total Targets: 41

Scientific Paper Hit Count for: HSP90, HSP90
6 Ashwagandha(Withaferin A)
4 Celastrol
2 Gambogic Acid
1 Deguelin
1 Quercetin
1 Sulforaphane (mainly Broccoli)
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:26  Cells:%  prod#:%  Target#:149  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page